Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib
Related Experiment Video
Updated: Dec 30, 2025
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
Hanping Wang1, Ruili Pan1, Xiaotong Zhang1
1Department of Respiratory Medicine, Peking Union Medical College Hospital, Beijing, China.
Background:
Abivertinib is a novel oral, third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that overcomes T790M-induced resistance in non-small cell lung cancer (NSCLC) patients. Here, we report the results of a complete and detailed clinical data of patients treated with abivertinib at our hospital in a phase I dose escalation/expansion study of abivertinib.
Methods:
NSCLC patients with the EGFR T790M mutation were orally administered abivertinib (150-300 mg) twice daily for cycles of 28 continuous days and tumor response was assessed. Further data regarding subsequent treatment protocols and survival were collected.
Results:
A total of 28 NSCLC patients were included. Of the 24 assessable patients, 12 (50%) achieved a partial response (PR), and six (25%) achieved stable disease (SD). Median progression-free survival (PFS) was 5.9 months (95% confidence interval (CI): 3.259-8.541) and median overall survival (OS) was 17.9 months (95% CI: 11.36-24.5). For salvage therapy in 15 (53.6%) patients after abivertinib, the median PFS following osimertinib treatment was 12 months. The median total treatment duration for the two third-generation EGFR TKIs was 15.9 months (95% CI: 12.5-19.3). The most frequent abivertinib-associated adverse effects were elevated hepatic transaminases (10/28, 35.7%) and diarrhea (10/28, 35.7%).
Conclusions:
Abivertinib is a unique novel third-generation EGFR TKI with good tolerance and efficacy in EGFR T790M(+) NSCLC patients. For patients with progressive disease after treatment with abivertinib, osimertinib could be an option for subsequent therapy but further studies are required.
Key Points:
Abivertinib is a novel third-generation EGFR TKI targeting the EGFR T790M mutation Abivertinib is well tolerated and efficacious in T790M-positive patients Abivertinib has a unique structure, efficacy, and resistance mechanism compared with osimertinib Osimertinib treatment after AC0010 showed a good response.
Insights
Abivertinib demonstrates good tolerance and efficacy in non-small cell lung cancer (NSCLC) patients with EGFR T790M mutations. Osimertinib may be a viable subsequent therapy option for patients experiencing progressive disease after abivertinib treatment.
Area of Science:
- Oncology
- Pharmacology
- Clinical Trials
Background:
- Abivertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
- It is designed to overcome T790M-induced resistance in non-small cell lung cancer (NSCLC).
Purpose of the Study:
- To report clinical data from a phase I study of abivertinib in NSCLC patients.
- To assess the efficacy and safety of abivertinib in patients with EGFR T790M mutations.
Main Methods:
- NSCLC patients with EGFR T790M mutation received oral abivertinib (150-300 mg) twice daily.
- Tumor response, survival data, and subsequent treatment protocols were assessed.
Main Results:
- Of 24 assessable patients, 50% achieved partial response and 25% achieved stable disease.
- Median progression-free survival was 5.9 months and median overall survival was 17.9 months.
- Common adverse effects included elevated hepatic transaminases and diarrhea.
Conclusions:
- Abivertinib shows good tolerance and efficacy in EGFR T790M-positive NSCLC patients.
- Osimertinib may be a subsequent therapy option for patients with progressive disease after abivertinib, warranting further investigation.
More Related Videos
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:27Tumor Immunotherapy
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...